References
- De Haro J, Bleda S, Varela C, et al. Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. Curr Med Res Opin 2016;32:1167-73
- Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
- Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
- Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
- Munir Pirmohamed. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006;62:509-11
- Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 1941;138:513-27
- Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis, 9th edition. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e44-88s
- Ansell J, Hirsh J, Hylek E, et al. The pharmacology and management of the vitamin K antagonists. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):160-98s
- Breckenridge A, Orme M, Wessling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-30
- Warfarin Prescribing Information. Princeton: Bristol-Myers Squibb. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf [Last accessed 11 August 2015]
- US Food and Drug Administration. FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa [online]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm467300.htm [Last accessed 18 November 2015]
- Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68